Manoj Wunnava, MD
Interventional Pain Medicine · Durham, NCNPI 1720263239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $346 and has fallen 74.3% since, to $89 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NC, where the typical reported total is $2,787.
Across 47 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$213
- Abbott$145
- Nevro Corp.$138
- Johnson & Johnson$125
- Collegium Pharmaceutical, Inc.$116
- Virtus Pharmaceuticals LLC$92
- plus $282 from 8 others
What the payments were for
- Food & beverage$1,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $213 |
| Abbott | 3 | $145 |
| Nevro Corp. | 6 | $138 |
| Johnson & Johnson | 2 | $125 |
| Collegium Pharmaceutical, Inc. | 6 | $116 |
| Virtus Pharmaceuticals LLC | 5 | $92 |
| Medtronic | 1 | $68 |
| Pfizer | 4 | $63 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| AbbVie | 3 | $38 |
| Valinor Pharma, LLC | 2 | $30 |
| Protega Pharmaceutials Inc | 1 | $16 |
| Amgen | 1 | $14 |
| Grifols USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,112 in reported general payments places this provider in the 25th percentile of 45 interventional pain medicine providers in North Carolina.
See all interventional pain medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 49 | $126,472 |
| OxycontinOxycodone Hcl | 58 | $56,441 |
| SpravatoEsketamine Hcl | 15 | $33,700 |
| Buprenorphine | 159 | $30,168 |
| MovantikNaloxegol Oxalate | 66 | $29,976 |
| NucyntaTapentadol Hcl | 27 | $28,167 |
| BelbucaBuprenorphine Hcl | 25 | $21,388 |
| Xtampza ErOxycodone Myristate | 18 | $10,215 |
| Oxycodone Hcl | 391 | $8,918 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 290 | $8,476 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 223 | $8,035 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $6,920 |
| Diclofenac Sodium | 30 | $5,887 |
| Gabapentin | 257 | $4,794 |
| Morphine Sulfate ErMorphine Sulfate | 122 | $3,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $92 | $126,47249 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er | $116 | $59,77070 claims |
| Johnson & JohnsonSpravato | $125 | $33,70015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 45 interventional pain medicine providers in North Carolina.
Other interventional pain medicine in Durham
- Timothy ChafinAhoskie$59K
- Robert WilsonSalisbury$37K
- John MansfieldAsheville$25K
- Erin ChaneyJacksonville$22K
- Kevin CostelloGreenville$22K
- Scott JohnstonJacksonville$20K
- Harsh GovilStatesville$19K
- Troy GingerichCharlotte$19K
- Brent HarkriderNew Bern$14K
- Carey-Walter ClossonCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.